Sumitomo Pharma Co.Ltd.TSE: 4506

Regarding a Report Concerning Sumitomo Pharma (The Company's Views on the GCR August 7 Report)

· Issued by Sumitomo Pharma Co.Ltd. via TDnet

Filed with TSE · · 1 page · English

Summary by 6ix AI

The company rejects the assertions made in the report, stating they are based on unilateral views and are unacceptable. Sumitomo Pharma emphasizes the reliability of the materials submitted for regulatory review of AMCHEPRY® and its ongoing post-marketing clinical study. The company plans to take appropriate actions, including legal measures, against misleading information to protect its interests and those of its shareholders.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Sumitomo Pharma Co.Ltd. on 6ix

Story so far

Earlier from Sumitomo Pharma Co.Ltd

Later from Sumitomo Pharma Co.Ltd

All Sumitomo Pharma Co.Ltd news releases